Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 486

1.

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.

Aminizadeh E, Alavian SM, Akbari Sari A, Ebrahimi Daryani N, Behnava B.

Hepat Mon. 2016 Mar 6;16(3):e28537. doi: 10.5812/hepatmon.28537. eCollection 2016 Mar. Review.

2.

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.

Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO.

PLoS One. 2016 Apr 21;11(4):e0153895. doi: 10.1371/journal.pone.0153895. eCollection 2016.

3.

KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver (KASL).

Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28. Review. No abstract available.

4.

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.

Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, Simons BC, Spradling PR, McMahon BJ.

Int J Circumpolar Health. 2016 Mar 29;75:30696. doi: 10.3402/ijch.v75.30696. eCollection 2016.

5.

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group.

PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016.

6.

Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.

Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T.

PLoS One. 2016 Mar 22;11(3):e0151828. doi: 10.1371/journal.pone.0151828. eCollection 2016.

7.

Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China.

Yang L, Jiang C, Hu S, Diao Q, Li J, Si W, Chen M, Zhao RY.

Int J Mol Sci. 2016 Mar 18;17(3). pii: E403. doi: 10.3390/ijms17030403.

8.

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.

Asselah T, Thompson AJ, Flisiak R, Romero-Gomez M, Messinger D, Bakalos G, Shiffman ML.

PLoS One. 2016 Mar 18;11(3):e0150569. doi: 10.1371/journal.pone.0150569. eCollection 2016.

9.

Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study.

Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES.

Balkan Med J. 2016 Jan;33(1):18-26. doi: 10.5152/balkanmedj.2015.15859. Epub 2016 Jan 1.

10.

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.

Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT, Shi KQ, Zheng MH.

Medicine (Baltimore). 2016 Mar;95(9):e3004. doi: 10.1097/MD.0000000000003004.

11.

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.

Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ.

CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):65-73. doi: 10.1002/psp4.12058. Epub 2016 Feb 2.

12.

Bibliometric analysis of the top-cited gastroenterology and hepatology articles.

Azer SA, Azer S.

BMJ Open. 2016 Feb 8;6(2):e009889. doi: 10.1136/bmjopen-2015-009889.

13.

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.

Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C.

Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):597-609. doi: 10.1007/s10096-016-2576-1. Epub 2016 Feb 6.

14.
15.

Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.

Chen R, Kobewka M, Addison W, Lachance G, Tyrrell DL.

PLoS One. 2016 Jan 14;11(1):e0147007. doi: 10.1371/journal.pone.0147007. eCollection 2016.

16.

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM.

Br J Clin Pharmacol. 2016 May;81(5):929-40. doi: 10.1111/bcp.12873. Epub 2016 Feb 24.

PMID:
26710243
17.

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.

Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M.

PLoS One. 2015 Dec 23;10(12):e0145622. doi: 10.1371/journal.pone.0145622. eCollection 2015.

18.

The role of HCV proteins on treatment outcomes.

Kumthip K, Maneekarn N.

Virol J. 2015 Dec 15;12:217. doi: 10.1186/s12985-015-0450-x.

19.

A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study.

Southern WN, Norton B, Steinman M, DeLuca J, Drainoni ML, Smith BD, Litwin AH.

BMC Infect Dis. 2015 Dec 1;15:553. doi: 10.1186/s12879-015-1283-3.

20.

A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of therasnostic agents.

Wang H, Agarwal P, Zhao S, Yu J, Lu X, He X.

Nat Commun. 2015 Dec 1;6:10081. doi: 10.1038/ncomms10081. Erratum in: Nat Commun. 2016;7:10350.

Items per page

Supplemental Content

Write to the Help Desk